<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">OJMC</journal-id><journal-title-group><journal-title>Open Journal of Medicinal Chemistry</journal-title></journal-title-group><issn pub-type="epub">2164-3121</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ojmc.2018.82002</article-id><article-id pub-id-type="publisher-id">OJMC-85108</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Chemistry&amp;Materials Science</subject></subj-group></article-categories><title-group><article-title>
 
 
  Determination of Azacitidine by Spectrophotometric Method
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>B.</surname><given-names>Ramachandra</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>N.</surname><given-names>Venkatasubba Naidu</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>Department of Chemistry, Annamacharya Institute of Technology and Sciences, Tirupati, India</addr-line></aff><aff id="aff2"><addr-line>Department of Chemistry, S. V. University, Tirupati, India</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>dr.ramachandrarajubandi@gmail.com(BR)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>06</day><month>06</month><year>2018</year></pub-date><volume>08</volume><issue>02</issue><fpage>15</fpage><lpage>21</lpage><history><date date-type="received"><day>20,</day>	<month>February</month>	<year>2018</year></date><date date-type="rev-recd"><day>3,</day>	<month>June</month>	<year>2018</year>	</date><date date-type="accepted"><day>6,</day>	<month>June</month>	<year>2018</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Simple, selective and sensitive spectrophotometric method has been developed for the determination of Azacitidine in pharmaceutical formulations and blood with MBTH (3-methyl-2-benzothiazolone hydrazone hydrochloride) reagent, at P
  <sup>H</sup>
  -4.0 which is extractable at 620 nm. Beer’s law is obeying in the concentration ranges 10 - 35 μg
  &#183;ml
  <sup>-1</sup> for formulations and 4 - 24 μg
  &#183;ml
  <sup>-1</sup> for blood sample. %R.S.D was found to be 0.0240%, 0.0610 and Recovery 99.82% 99.24% respectively. The method was completely validated and proven to be rugged. The interferences of the other ingredients and excipients were not observed. The repeatability and the performance of the proven method were conventional by point and interior proposition and through recovery studies.
 
</p></abstract><kwd-group><kwd>UV-Visible Spectrophotometry</kwd><kwd> Azacitidine</kwd><kwd> Blood Sample</kwd><kwd> MBTH/FeCl&lt;SUB&gt;3&lt;/SUB&gt; and Oxidative Coupling Reaction</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Azacitidine is a pyrimidine nucleoside analog of cytidine. An antitumor nucleoside approves by FDA for the action of myelodysplastic disorder [<xref ref-type="bibr" rid="scirp.85108-ref1">1</xref>] . It is chemically 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydro-1,3,5-triazin-2-one (<xref ref-type="fig" rid="fig1">Figure 1</xref>) with molecular weight of 244.205 g/mol. Clinically, it has also verified activity against various solid tumors as well as leukemia [<xref ref-type="bibr" rid="scirp.85108-ref2">2</xref>] . Potential combinations include use of a hypomethylating agent with histone deacetylase inhibitors, such as phenyl butyrate [<xref ref-type="bibr" rid="scirp.85108-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.85108-ref4">4</xref>] . The literature survey exposed that Azacitidine was determined by Liquid chromatography-mass spectrometry [<xref ref-type="bibr" rid="scirp.85108-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.85108-ref6">6</xref>] , HPLC [<xref ref-type="bibr" rid="scirp.85108-ref7">7</xref>] [<xref ref-type="bibr" rid="scirp.85108-ref8">8</xref>] , instrumental methods and spectrophotometric method using oxidative coupling reaction [<xref ref-type="bibr" rid="scirp.85108-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.85108-ref10">10</xref>] [<xref ref-type="bibr" rid="scirp.85108-ref11">11</xref>] . At</p><p>present, the authors have proposed three simple UV Spectrophotometric methods for the analysis of Azacitidine in tablets and validated as per ICH guidelines [<xref ref-type="bibr" rid="scirp.85108-ref12">12</xref>] .</p></sec><sec id="s2"><title>2. Materials and Methods</title><p>UV-VIS spectrophotometer (UV-1800 Shimandzu, North America) connected to computer loaded with spectra manager software vision light was employed with spectral bandwidth of 1 nm and wavelength accuracy of &#177;0.3 nm with a pair of 10 mm matched quartz cells. For scanning, the wavelength range selected was 400 nm to 200 nm with medium scanning speed. All weights were taken using electronic balance (Denver, Germany). All experiments were performed at room temperature (25 &#177; 1)˚C. The pure samples were collected from Analog labs, Hyderabad, India for providing the drug samples.</p><sec id="s2_1"><title>2.1. Preparation of Stock and Sample Solution</title><p>Azacitidine was obtained as gift sample from analog labs Hyderabad, India. Azacitidine stock was prepared by dissolving 100 mg in 100 ml of methanol (1000 &#181;g∙ml<sup>−1</sup>). 10 ml of aliquot was taken into a 100 ml of volumetric flask and made up to the mark with methanol. (100 &#181;g∙ml<sup>−1</sup>). Samples of aforesaid solutions ranging from 1 - 3.5 ml (10 - 35 &#181;g∙ml<sup>−1</sup>) were transferred in to 10 ml volumetric flasks. 1 ml of (0.5%) MBTH solution was added followed by 1 ml of (0.7%) Ferric chloride solution and then to each flask made up to the mark with acetonitrile. The resulting solutions were heated and finally 1 ml (0.5 N) hydrochloric acid solution was added. The solutions were cooled to room temperature and made up to the mark with methanol. The color species was stable for 32 h. The absorbance of green colored chromogen was measured at 620 nm against the reagent blank. The amount of azacitidine present in the sample solution was computed from its calibration curve.</p></sec><sec id="s2_2"><title>2.2. Procedure for Blood Sample</title><p>Blood samples collected were centrifuged. To isolate Azacitidine from plasma, methanol was used for protein precipitation. Liquid-Liquid extraction was performed with plasma by alkalinization with 1 M NaOH (sodium hydroxide), using by extraction with 30% dichloromethane in hexane. The upper organic layer was evaporated to dryness. The dry residue of 100 mg was dissolved in 100 ml of methanol (1000 &#181;g∙ml<sup>−1</sup>). 10 ml of aliquot was taken into a 100 ml of volumetric flask and made up to the mark with methanol. (100 &#181;g∙ml<sup>−1</sup>). The samples of aforesaid solutions ranging from 0.4 - 2.4 ml (4 - 24 &#181;g∙ml<sup>−1</sup>) were transferred in to 10 ml volumetric flasks. 1 ml of (0.5%) MBTH solution was added followed by 1 ml of (0.7%) Ferric chloride solution and then to each flask made up to the mark with acetonitrile. The resulting solutions were heated and finally 1 ml (0.5 N) hydrochloric acid solution was added. The solutions were cooled to room temperature and made up to the mark with methanol. The color species was stable for 32 h. The absorbance of green colored chromogen was measured at 620 nm against the reagent blank. The amount of azacitidine present in the sample solution was computed from its calibration curve.</p></sec></sec><sec id="s3"><title>3. Procedure</title><p>Linearity of the method was established by preparing a calibration curve. For this a series of drug solutions were prepared 10 - 35 &#181;g∙ml<sup>−1</sup> scanned (400 - 800 nm) against their reagent blank. The functional group used for the color development for this method was primary amine group. A schematic reaction mechanism of azacitidine with MBTH reagent was shown in Scheme 1. The absorption spectrum was recorded and shows minima at 620 nm therefore the amplitude was chosen for all the analytical determinations in this method. The precision study was done by recording the absorbance of six replicates for the proposed method. (20 &#181;g∙ml<sup>−1</sup>) and the %RSD was calculated. Accuracy was</p><disp-formula id="scirp.85108-formula1"><graphic  xlink:href="//html.scirp.org/file/1-1790114x3.png"  xlink:type="simple"/></disp-formula><p>Scheme 1. Schematic reaction mechanism of Azacitidine with MBTH/FeCl<sub>3</sub>.</p><p>evaluated from the percent recovery studies by the addition of 80%, 100% and 120% of pure sample solution to the pre-analyzed formulation solution. Azacitidine drug solution from the formulation (10 &#181;g∙ml<sup>−1</sup>) was spiked with 80%, 100% and 120% of pure API solution and the % recovery was calculated.</p></sec><sec id="s4"><title>4. Results and Discussion</title><p>The absorption spectrum of Azacitidine was shown in <xref ref-type="fig" rid="fig2">Figure 2</xref> indicating absorption wavelength 620 nm. A graph was drawn by taking the concentration on the x-axis and the corresponding absorbance on the y-axis for the data obtained in this method, Beer-Lambert’s law was obeyed over the concentration ranges 10 - 35 &#181;g∙ml<sup>−1</sup> for formulations and 4 - 24 &#181;g∙ml<sup>−1</sup> for blood samples groups were shown in (<xref ref-type="fig" rid="fig3">Figure 3</xref> &amp; <xref ref-type="fig" rid="fig4">Figure 4</xref>). The linear regression equations for the method was found to be y = 0.04114 &#215; 0.002658, R<sup>2</sup> = 0.9992. The %RSD in precision and accuracy studies was found to be less than 2%. This method was indicating</p><p>that the method was more precise and accurate. The optical characteristics were shown in <xref ref-type="table" rid="table1">Table 1</xref>. The % recovery was 99.82 in formulations and 99.24 in blood samples and the result are given in Tables 2-4.</p></sec><sec id="s5"><title>5. Conclusion</title><p>The method is found to be accurate and precise, as indicated by recovery studies close to 100 and % RSD is not more than 2. The summery of validation parameters of proposed UV-Visible spectrophotometric method is given. The proposed UV-Visible spectrophotometric method used for the determination of azacitidine as bulk, Commercial samples and blood samples has been developed. The</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Optical characteristics of Azacitidine</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Parameter</th><th align="center" valign="middle" >MBTH method</th></tr></thead><tr><td align="center" valign="middle" >Color</td><td align="center" valign="middle" >Green</td></tr><tr><td align="center" valign="middle" >Absorption maxima (nm)</td><td align="center" valign="middle" >620</td></tr><tr><td align="center" valign="middle" >Beer’s law limits (&#181;g∙ml<sup>−1</sup>)</td><td align="center" valign="middle" >10-35</td></tr><tr><td align="center" valign="middle" >Molar absorptivity (l mol<sup>−1</sup>∙cm<sup>−1</sup>)</td><td align="center" valign="middle" >0.0409 &#215; 10<sup>4 </sup></td></tr><tr><td align="center" valign="middle" >Sandell’s Sensitivity (&#181;g∙cm<sup>−&#173;2</sup>)</td><td align="center" valign="middle" >1.6781</td></tr><tr><td align="center" valign="middle" >Regression equation (Y*)</td><td align="center" valign="middle" >Y = mx + c</td></tr><tr><td align="center" valign="middle" >Slope (b)</td><td align="center" valign="middle" >0.04114</td></tr><tr><td align="center" valign="middle" >Intercept(a)</td><td align="center" valign="middle" >0.00685</td></tr><tr><td align="center" valign="middle" >Standard deviation(SD)</td><td align="center" valign="middle" >0.00765</td></tr><tr><td align="center" valign="middle" >Correlation coefficient (r<sup>2</sup>)</td><td align="center" valign="middle" >0.999</td></tr><tr><td align="center" valign="middle" >%RSD (Relative Standard deviation)</td><td align="center" valign="middle" >0.0240</td></tr><tr><td align="center" valign="middle" >Limits of detection (LOD)(&#181;g∙ml<sup>−1</sup>)</td><td align="center" valign="middle" >0.61376</td></tr><tr><td align="center" valign="middle" >Limits of quantification (LOQ) (&#181;g∙ml<sup>−1</sup>)</td><td align="center" valign="middle" >1.8595</td></tr></tbody></table></table-wrap><p>% RSD of six independent determinations.</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Assay results of Azacitidine in formulations and Blood samples by visible Method</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Name of the formulation</th><th align="center" valign="middle" >Formulation in (mg)</th><th align="center" valign="middle" >Amount found by the proposed method (mg)</th><th align="center" valign="middle" >Amount found by the reference method<sup>9−11</sup> (mg)</th><th align="center" valign="middle" >% Recovery</th></tr></thead><tr><td align="center" valign="middle" >VIDAZA</td><td align="center" valign="middle" >250</td><td align="center" valign="middle" >249.25 t = 0.00296 F = 6.38481</td><td align="center" valign="middle" >248.75</td><td align="center" valign="middle" >99.25</td></tr><tr><td align="center" valign="middle" >VIDAZA</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >1.62 t = 0.00296 F = 6.2307</td><td align="center" valign="middle" >1.60</td><td align="center" valign="middle" >99.62</td></tr></tbody></table></table-wrap><p>T and F-values refer to comparison of the proposed method with reference method; Theoretical values at 95% confidence limits t= 0.00297 and F = 5.9177 (Formulations); Theoretical values at 95% confidence limits t = 0.00269 and F = 5.6976 (Blood samples).</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Determination of accuracy of Azacitidine</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Amount of AZC in formulation (mg)</th><th align="center" valign="middle" >Amount of Standard AZC added (mg)</th><th align="center" valign="middle" >Total amount found (mg)</th><th align="center" valign="middle" >% Recovery</th></tr></thead><tr><td align="center" valign="middle" >249.90</td><td align="center" valign="middle" >200</td><td align="center" valign="middle" >449.82</td><td align="center" valign="middle" >99.82</td></tr><tr><td align="center" valign="middle" >249.91</td><td align="center" valign="middle" >250</td><td align="center" valign="middle" >499.82</td><td align="center" valign="middle" >99.82</td></tr><tr><td align="center" valign="middle" >249.93</td><td align="center" valign="middle" >300</td><td align="center" valign="middle" >549.84</td><td align="center" valign="middle" >99.84</td></tr></tbody></table></table-wrap><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Determination of accuracy of Azacitidine</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Name of the Formulation in (mg)</th><th align="center" valign="middle" >Amount of Drug in Blood sample (mg)</th><th align="center" valign="middle" >Amount of Standard Drug added in (mg)</th><th align="center" valign="middle" >Total amount found (mg)</th><th align="center" valign="middle" >% Recovery</th></tr></thead><tr><td align="center" valign="middle" >VIDAZA (2 mg)</td><td align="center" valign="middle" >1.62</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >3.24</td><td align="center" valign="middle" >99.24</td></tr></tbody></table></table-wrap><p>method may be recommended for routine and quality control analysis of the investigated pure in bulk and blood samples. The analytical solution is found to be stable up to 32 Hrs at room temperature. Hence, it is concluded that the analytical method is validated and can be used for routine analysis.</p></sec><sec id="s6"><title>Acknowledgements</title><p>The authors are grateful to Annamacharya Institute of Technology and Sciences, Tirupati-517520.A.P., India for providing necessary research facilities and to Analog labs Hyderabad, India for providing the drug samples.</p></sec><sec id="s7"><title>Cite this paper</title><p>Ramachandra, B. and Naidu, N.V. (2018) Determination of Azacitidine by Spectrophotometric Method. Open Journal of Medicinal Chemistry, 8, 15-21. https://doi.org/10.4236/ojmc.2018.82002</p></sec></body><back><ref-list><title>References</title><ref id="scirp.85108-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Cihak, A. (1974) Biological Effects of 5-Azacytidine in Eukaryotes. Oncology, 30, 405-422. https://doi.org/10.1159/000224981</mixed-citation></ref><ref id="scirp.85108-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">McCredie, B., Bodey, G.P., Burgess, M.A., Gutterman, J.U., Kodriguez, V., Sullivan, M. and Freireich, E. (1973) Treatment of Acute Leukemia with 5-Azacytidine (NSC-102816). Cancer Chemotherapy Reports, 57, 319-323.</mixed-citation></ref><ref id="scirp.85108-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Zhu, W.G., Lakshmanan, R.R., Beal, M.D. and Otterson, G.A. (2001) DNA Methyl Transferase Inhibition Enhances Apoptosis Induced by Histone Deacetylase Inhibitors. Cancer Research, 61, 1327-1333.</mixed-citation></ref><ref id="scirp.85108-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Cameron, E.E., Bachman, K.E., Myohanen, S., Herman, J.G. and Baylin, S.B. (1999) Synergy of Demethylation and Histone Deacetylase Inhibition in the Re-Expression of Genes Silenced in Cancer. Nature Genetics, 21, 103-107.</mixed-citation></ref><ref id="scirp.85108-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Satyanarayana Raju, T., Kalyanaraman, L., Raghavachary, K.S.V. and Yadagiri Swamy, P. (2012) A Novel Normal Phase HPLC Method for the Quantification of N-Formyl Impurity in Azacitidine Active Pharmaceutical Ingredients and Pharmaceutical Dosage Forms. Journal of Liquid Chromatography &amp; Related Technologies, 35, 1070-1080.</mixed-citation></ref><ref id="scirp.85108-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Zhao, M., Rudek, M.A., He, P., Hartke, C., Gore, S., Carducci, M.A. and Baker, S.D. (2004) Quantification of 5-Azacytidine in Plasma by Electrospray Tandem Mass Spectrometry Coupled with High-Performance Liquid Chromatography. Journal of Chromatography B, 813, 81-88.</mixed-citation></ref><ref id="scirp.85108-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Kissinger, L.D. and Stemm, N.L. (1986) Determination of the Antileukemia Agents Cytarabine and Azacitidine and Their Respective Degradation Products by High-Performance Liquid Chromatography. Journal of Chromatography A, 353, 309-318. https://doi.org/10.1016/S0021-9673(01)87101-6</mixed-citation></ref><ref id="scirp.85108-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Chan, K.K., Giannini, D.D., Staroscik, J.A. and Sadee, W. (1979) 5-Azacytidine Hydrolysis Kinetics Measured by High-Pressure Liquid Chromatography and 13C-NMR Spectroscopy. Journal of Pharmaceutical Sciences, 68, 807-812.  
https://doi.org/10.1002/jps.2600680705</mixed-citation></ref><ref id="scirp.85108-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Chatwal, G.R. and Anand, S.K.J. (2003) Instrumental Methods of Chemical Analysis. Himalaya Publishing House, Mumbai, 2.108-2.109.</mixed-citation></ref><ref id="scirp.85108-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Harris, D.C. (2003) Quantitative Chemical Analysis. 6th Edition, W. H. Freeman. 258-261.</mixed-citation></ref><ref id="scirp.85108-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Sastry, C.S.P. and Rao, K.R. (2003) Determination of Cefadroxil by Tree Simple Spectrophotometric Method Using Oxidative Coupling Reaction. Microchimica Acta, 126, 167-172. https://doi.org/10.1007/BF01242680</mixed-citation></ref><ref id="scirp.85108-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">(2005) International Conference on Harmonization of Technical Requirements for the Registration of Pharmaceutical for Human Use: Validation of Analytical Procedures, Text and Methodolo-gy-Q2-R1.</mixed-citation></ref></ref-list></back></article>